Thermally Stable Cholinesterase Production via Cell-Free Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing cholinesterases for detoxification and decontamination of organophosphorus compounds are inefficient, as they require large quantities and are not cost-effective, with transgenic animals and plants facing issues of immunogenicity and low expression levels.
Innovation Solution
Expressing cholinesterase polynucleotide sequences with a tetramerization domain and a proline-rich attachment domain (PRAD) along with a targeting sequence, such as SEKDEL, to enhance both expression and thermal stability, allowing for large-scale production in transient expression systems in prokaryotic, mammalian, or plant cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If transgenic animals or plants are used to produce cholinesterases, then large quantities of enzyme can be produced, but the expression levels are low and the products are immunogenic
Solution Approach 1:
The patent uses cell-free expression systems to copy and produce cholinesterase proteins without requiring transgenic organisms. This approach synthesizes functional cholinesterase proteins in vitro using purified components, avoiding the immunogenicity issues associated with transgenic animals and plants while achieving high expression levels
Solution Approach 2:
The patent introduces plasmid DNA as an intermediary carrier containing the cholinesterase gene sequence. This plasmid serves as a temporary vector to deliver and express the enzyme gene in non-transgenic systems, enabling high-level expression without the need for stable transgenic integration that causes immunogenicity
2Ease of manufacture
If conventional cholinesterase production methods are used, then production can proceed, but the cost is high and purification is required
Solution Approach 1:
The cell-free expression system is designed to be self-contained with all necessary components (ribosomes, tRNA, enzymes, energy sources) included in the reaction mixture. This eliminates the need for complex transgenic animal or plant breeding programs, reducing both cost and time while achieving high yields without extensive purification requirements
Solution Approach 2:
The patent segments the production system into separate, optimizable components: plasmid DNA preparation, cell-free extract preparation, and expression reaction components. This modular approach allows each component to be independently optimized for cost-effectiveness and yield while simplifying the overall manufacturing process
Data Source
AI summary
Disclosed herein are methods for the large-scale production of a highly thermally stable acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Additionally, the expression methods disclosed herein can produce ChE preparations consisting of extract or purified forms that can be produced in high amounts and are highly thermally stable. These ChE products can be used in vitro detection, detoxification and decontamination methods.